Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPSI - Cancer Related Major Depression Treated With a Single Dose of Psilocybin
NCT06319378Phase 2Recruiting
- Start
- Apr 2024
- Primary completion
- Dec 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of psilocybin in major depressive disorder (MDD) (2 arms). Primary endpoint: Montgomery-Åsberg Depression Rating Scale at Day 42. Started Apr 2024; status: recruiting.
02
Drugs
psilocybin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06319378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06319378.